Bucillamine's success is still priced in Looking at the field of Psych stocks RVV still has 20-30% of it's value priced in from the success of the BUC trial.
With the new projected completed being the last day of Q1, I would enjoy revisiting 2021 promises but I waste of key presses, needless to say, NO TARGETS WERE MET in '21.
Pfizer is very close to getting the nod on their anti-viral pill in Canada and much of the world. RVV didn't bother recruiting in Canada, Turkey seemed a better venue I suppose. I wonder if the FDA agrees?
Recently someone posted an article which offered the stipend provided by RVV. It seems to me to be a very reasonable sum leaving me to believe MF raised said stipend recently, realizing that the stipend ensures trial envolvement and completion.
Its not like using the toe iron to ensure a sweet score on the back 9, is it MF?
Looks to be a wee bit of support at 29.5. 29 cents will trigger stop loses down to 24-26 cents. In my opinion that is about fair value with the latest trial update.